Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

anagrelide × 1 year × Clear all

Phase

Status

Active not recruiting 1

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Thrombocythemia, Essential 1 Myeloproliferative Disorders 1

Interventions

pembrolizumab 1128 Specimen Handling 797 Carboplatin 751 Magnetic Resonance Spectroscopy 723 Cyclophosphamide 721 Cisplatin 642 Nivolumab 630 Paclitaxel 563 Radiotherapy 534 Gemcitabine 500 Biopsy 484 Bevacizumab 424 Dexamethasone 401 Docetaxel 353 fludarabine 351 venetoclax 344 atezolizumab 329 Fluorouracil 328 Oxaliplatin 327 Capecitabine 322 Rituximab 315 durvalumab 302 Drug Therapy 299 Doxorubicin 285 Radiosurgery 285 Pemetrexed 282 Ipilimumab 277 Standard of Care 276 Blood Specimen Collection 274 Radiation 259

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT04285086 2025-08-13

SURPASS ET

PharmaEssentia

Phase 3 Active not recruiting

Myeloproliferative Disorders, Thrombocythemia, Essential

Data powered by HemOnc (CC BY 4.0) Colophon ⚡